Evidence map›Paper›PMID 28577037›Full record

ArticleLung2017

Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.

Katherine M Marsh, David Schipper, Alice S Ferng, Kitsie Johnson, Julia Fisher, Shannon Knapp, Destiny Dicken, Zain Khalpey

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Katherine M MarshDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.
David SchipperDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Alice S FerngDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Kitsie JohnsonDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Julia FisherStatistical Consulting Lab, BIO5 Institute, University of Arizona, Tucson, AZ, USA.
Shannon KnappStatistical Consulting Lab, BIO5 Institute, University of Arizona, Tucson, AZ, USA.
Destiny DickenDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Zain KhalpeyDivision of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA. zkhalpey@surgery.arizona.edu.ORCID 0000-0003-1231-1028
University of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that predominantly affects women of childbearing age. Exogenous rapamycin (sirolimus) has been shown to improve clinical outcomes and was recently approved to treat LAM, whereas estrogen (E

methodsOxygen consumption rates (OCR) and redox potential were measured to determine metabolic state across control cells, MEF +/+ and -/- cells treated with rapamycin (Rapa), and MEF +/+ and -/- cells treated with E

resultsOCR of MEF -/- cells treated with rapamycin (MEF -/- Rapa) versus MEF -/- control were significantly lower across all conditions. The static oxidation reduction potential of the MEF -/- Rapa group was also lower, approaching significance. The coupling efficiency and ratio of ATP-linked respiration to maximum respiration were statistically lower in MEF -/- Rapa compared to MEF +/+ Rapa. There were no significant metabolic findings across any of the MEF cells treated with E

conclusionMEF cells are thought to be a feasible metabolic model for LAM, which has implications for future pharmacologic and biologic testing.

Indexed as

Adenosine TriphosphateAnimalsCells, CulturedDisease ProgressionEnergy MetabolismEstradiolFibroblastsGenetic Predisposition to DiseaseLung NeoplasmsLymphangioleiomyomatosisMice, KnockoutOxidation-ReductionOxygen ConsumptionPhenotypeSirolimusTuberous Sclerosis Complex 2 ProteinAdenosine TriphosphateEstradiolSirolimusTsc2 protein, mouseTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsLymphangioleiomyomatosisMetabolismmTORRapamycinSirolimus

Identifiers

PMID28577037
OpenAlexW2620564313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.